What it sells
Platform injectable gel based therapeutic for osteoarthritis
Business model breakdown
Buyer: who owns the budget?
UnverifiedEventual payers: health systems/insurers via approved drug; near-term funding by investors (Y Combinator backed).
Trigger: what makes them buy now?
Chronic osteoarthritis pain where current treatments fall short; TRPV1 agonists limited by burning on administration which the prodrug addresses.
Workflow: what inputs become what output?
Lead RM-010: non-opioid TRPV1 prodrug injected intra-articularly into the knee to desensitize pain-signaling nerve fibers; pipeline also covers urology via injectable, instillation and topical routes.
Economics: what it saves and how it charges
UnverifiedPre-revenue biotech; value from advancing RM-010 through preclinical/pre-IND to clinic, then licensing or sale.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2022 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.